BHCM
ENTA icon

Brevan Howard Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Brevan Howard Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,333
Closed -$198K – 1142
2024
Q1 		$198K Sell
11,333
-1,058
-9% -$14K ﹤0.01% 808
2023
Q4 		$117K Buy
+12,391
New +$115K ﹤0.01% 939

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Brevan Howard Capital Management's ENTA Position: Q2 2024 in Review

Brevan Howard Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q2 2024, closing a stake of 11,333 shares — an estimated $198K sold.

Brevan Howard Capital Management first reported a position in ENTA in Q4 2023 and held it in 2 quarters. The position peaked at $198K in Q1 2024. 100 funds tracked by Wall St. Rank hold ENTA as of Q2 2024.

  • Brevan Howard Capital Management reported no remaining Enanta Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Brevan Howard Capital Management sold 11,333 Enanta Pharmaceuticals shares in Q2 2024, an estimated $198K.
  • Brevan Howard Capital Management first reported a position in Enanta Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Brevan Howard Capital Management's Enanta Pharmaceuticals position peaked at $198K in Q1 2024.
  • 100 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2024.

Based on Brevan Howard Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.